Compounds which selectively modulate the CB2 receptor
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.
1. A compound of the formula (I)
wherein:
ring A is a 5-membered heteroaryl ring;
R 1 is hydrogen, C 1-10 alkyl or C 3-10 cycloalkyl which is optionally substituted with 1-3 C 1-10 alkyl, each R 1 or it's substituent is optionally halogenated;
R 2 is methyl substituted with 1 heterocyclyl, each substituent on R 2 where possible is optionally halogenated or substituted with 1 to 3 C 1-6 alkyl, C 1-6 acyl, C 1-6 alkyl sulfonyl, cyano, aryl, oxo or hydroxyl;
R 3 and R 3 ′ are independently hydrogen or C 1-6 alkyl optionally halogenated with the proviso that R 3 and R 3 ′ cannot simultaneously be hydrogen;
R 4 is hydrogen or methyl;
R 5 is chosen from
m is 0, 1, 2 or 3;
R 6 is hydrogen, C 1-4 alkyl or C 1-4 alkoxy;
R 7 and R 8 are each independently hydrogen, or C 1-4 alkyl with the proviso that both R 7 and R 8 cannot be hydrogen; and wherein R 7 and R 8 optionally can cyclize to form a C 3-7 cycloalkyl ring;
R 9 is C 1-6 alkyl or aryl;
ring B is a 5-6 membered heterocyclic ring;
n is 0, 1 or 2;
wherein any carbon atom on the formula (I) or any R substituent listed above is optionally partially or fully halogenated where possible;
or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1 and wherein
ring A is
R 2 is methyl substituted with 1 heterocyclyl chosen from tetrahydropyranyl, dioxanyl, tetrahydrofuranyl, thiomorpholinyl, 1,1-dioxo-1λ 6 -thiomorpholinyl, morpholinyl, pyrrolidinyl, piperidinyl and piperazinyl,
each R 2 substituent where possible is optionally halogenated or substituted with 1 to 3 C 1-5 alkyl, C 1-5 acyl, methyl sulfonyl, cyano, phenyl, oxo or hydroxyl;
R 3 and R 3 ′ are each methyl or ethyl, each optionally halogenated.
3. The compound according to claim 2 and wherein
ring A is
R 1 is hydrogen or C 1-3 alkyl optionally halogenated;
R 2 is methyl substituted with 1 heterocyclyl chosen from tetrahydropyranyl, dioxanyl, tetrahydrofuranyl, thiomorpholinyl, 1,1-dioxo-1λ 6 -thiomorpholinyl, morpholinyl, pyrrolidinyl, piperidinyl and piperazinyl each optionally halogenated or substituted with C 1-4 alkyl or methyl sulfonyl;
R 3 and R 3 ′ are each methyl or ethyl;
R 6 is hydrogen or C 1-2 alkyl;
R 7 and R 8 are each C 1-2 alkyl.
4. The compound according to claim 3 and wherein
ring A is
R 2 is methyl optionally substituted with one heterocyclyl chosen from tetrahydropyranyl, dioxanyl, tetrahydrofuranyl, thiomorpholinyl, 1,1-dioxo-1λ 6 -thiomorpholinyl, morpholinyl, pyrrolidinyl, piperidinyl and piperazinyl each optionally halogenated or substituted with C 1-4 alkyl or methyl sulfonyl.
5. The compound according to claim 3 , and wherein
ring A is
R 3 and R 3 ′ are methyl;
R 6 is hydrogen or C 1-2 alkyl;
wherein R 7 and R 8 are each C 1-2 alkyl.
6. The compound according to claim 5 , and wherein
ring A is
7. The compound according to claim 6 and wherein
ring A is
8. The compound according to claim 2 , and wherein
R 2 is tetrahydrofuranyl-CH 2 —;
ring A is
R 5 is
wherein
wherein R 7 and R 8 optionally can cyclize to form a C 3-7 cycloalkyl ring.
9. The compound according to claim 2 , and wherein
ring A is
R 5 is
wherein
wherein R 7 and R 8 optionally can cyclize to form a C 3-7 cycloalkyl ring.
10. A compound of the formula (I) wherein the defintions: ring A, R 1 , R 2 , R 3 , R 3 ′, R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , m, ring B, and n are as defined in claim 1 and wherein R 7 and R 6 can cyclize to form a 4-6 membered heterocyclic ring.
11. A compound of the formula (II)
wherein
of the formula (II) is chosen from column A1-A8 in the table, and
of the formula (II) is chosen from column B1-B19 in the table,
A1
B1
A2
B2
A3
B3
A4
B4
A5
B5
A6
B6
A7
B7
A8
B8
B9
B10
B11
B12
B13
B14
B15
B16
B17
B18
B19
or a pharmaceutically acceptable salt thereof.
12. A compound chosen from
or a pharmaceutically acceptable salt thereof.
13. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 or 12 and one or more pharmaceutically acceptable carriers and/or adjuvants.
14. A method of treating pain comprising administering a therapeutically effective amount of a compound according to claim 1 or 12 .
15. The method according to claim 14 wherein pain is chosen from acute pain, visceral pain, neuropathic pain, inflammatory and nociceptive pain, cancer pain and headache.